Scientific Publications
TCR
IL-12
CAR-T
TCR
November 10, 2022
Society for Immunotherapy of Cancer (SITC) 2022
SUBJECT: TCR
September 30, 2022
CRI-ENCI-AACR (CICON22) Presentation by Dr. Marcelo Negrao
First two patients treated in TCR-T Library Phase 1/2 Trial had manageable safety profiles with no dose limiting toxicities; Patient 1 achieved a confirmed partial response, Patient 2’s achieved best overall response of stable disease
SUBJECT: TCR
September 21, 2022
Abstract: CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
First patient treated in TCR-T Library Phase ½ Trial achieved a confirmed partial response and Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed
SUBJECT: TCR
September 12, 2022
European Society of Medical Oncology (ESMO) 2022
Commencement of First-in-human Phase 1/2 TCR-T Clinical Trial Targeting Shared Tumor-specific Hotspot Mutations in Solid Tumors
SUBJECT: TCR
June 5, 2022
American Society of Clinical Oncology (ASCO) 2022
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors
SUBJECT: TCR
May 16, 2022
American Society for Gene and Cell Therapy (ASGCT) 2022
Stem-cell memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens generated through co-expression of membrane-bound Interleukin-15
SUBJECT: TCR
November 13, 2021
Society for Immunotherapy of Cancer (SITC) 2021
Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers
SUBJECT: TCR
June 9, 2021
Drew Deniger, Vice President of Immunology, presentation at the Federation of American Societies for Experimental Biology (FASEB) virtual conference held on Wednesday June 9, 2021, entitled “Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer”
SUBJECT: TCR
April 12, 2021
2021 Annual Meeting for American Association for Cancer Research (AACR)
SUBJECT: TCR
December 8, 2019
61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando
Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-expressing Membrane-bound IL-15 Yields Antitumor Responses
SUBJECT: TCR
June 16, 2016
The American Society of Gene & Cell Therapy
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
SUBJECT: TCR
Back to TOP
IL-12
November 19, 2021
2021 Society for Neuro-Oncology (SNO) Annual Meeting
Final Resultsof Controlled IL-12 Monotherapy and in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma.
SUBJECT: IL-12
November 19, 2020
2020 Society for Neuro-Oncology (SNO) Annual Meeting
Phase 2 Trial of Controlled IL-12 in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma.
SUBJECT: IL-12
Combination of Controlled Interleukin-12 Gene Therapy with Immune Checkpoint Blockade in Recurrent Glioblastoma: Updated Results of a Multi-Institutional, Open Label Phase 1 Trial.
SUBJECT: IL-12
Phase I/II Study of Controlled IL-12 as Immunotherapy for Diffuse Intrinsic Pontine Glioma (DIPG).
SUBJECT: IL-12
May 29, 2020
2020 American Society of Clinical Oncology (ASCO) Annual (Virtual) Meeting
Controlled IL-12 in Combination with a PD-1 Inhibitor: Subjects with Recurrent Glioblastoma
View poster discussion presented by E. Antonio Chiocca, M.D., Ph.D. (ASCO registration required)
Poster discussion presented by E. Antonio Chiocca, M.D., Ph.D. (video transcript)
SUBJECT: IL-12
Survival of Subjects with Recurrent Glioblastoma Receiving Intratumoral Administration of Controlled IL-12 with Limited Exposure to Dexamethasone
SUBJECT: IL-12
Final Results of Controlled IL-12 Monotherapy in Adults with Grade III or IV Gliomas
SUBJECT: IL-12
November 23, 2019
2019 Annual Meeting of the Society for Neuro-Oncology (SNO) in Phoenix
Survival of Subjects with Recurrent Glioblastoma Receiving Intra-tumoral Administration of IL-12 Managed with Low-dose Dexamethasone
SUBJECT: IL-12
PD-1 Inhibition can be Combined with IL-12 in Subjects with Recurrent Glioblastoma
SUBJECT: IL-12
August 14, 2019
Science Translational Medicine
Regulatable Interleukin-12 Gene Therapy in Patients With Recurrent High-Grade Glioma: Results of a Phase 1 Trial
SUBJECT: IL-12
June 02, 2019
2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago
Evaluation of Controlled IL-12 as Monotherapy in Subjects with Recurrent GBM
SUBJECT: IL-12
Evaluation of Controlled IL-12 in Combination with PD-1 Inhibitor in Subjects with Recurrent GBM
SUBJECT: IL-12
November 16, 2018
23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) in New Orleans
A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adults with recurrent glioblastoma: Dose determination with updated overall survival
SUBJECT: IL-12
June 01, 2018
2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL
Demonstration of anti-tumor immunity via intratumoral regulated platform Ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients
SUBJECT: IL-12
May 14, 2018
Cancer Gene Therapy
Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for treatment of glioma
SUBJECT: IL-12
October 10, 2016
European Society for Medical Oncology (ESMO) 2016 Congress
Phase 1b/2 study of intratumoral Ad-RTS-hIL-12+veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer
SUBJECT: IL-12
September 16, 2015
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival
Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 in advanced breast cancer and melanoma patients
SUBJECT: IL-12
December 01, 2014
AACR Special Conference
Ad-RTS-hIL-12 + Veledimex Regulation of IL-12 Expression in Advanced Breast Cancer and Melanoma
SUBJECT: IL-12
May 21, 2013
2013 Annual Meeting of the American Society of Clinical Oncology (ASCO
A Phase I Open-Label Study of Ad-RTS-hIL-12, an Adenoviral Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand in Subjects with Unresectable Stage III/IV Melanoma
SUBJECT: IL-12
May 15, 2013
ASGCT Annual Meeting 2013
Nonclinical and Phase I Clinical Studies with a Regulated Adenoviral Gene Delivery of IL-12 Show Promising Clinical Activity in Unresectable Stage III/IV Melanoma
SUBJECT: IL-12
Back to TOP
CAR-T
March 12, 2020
SUBJECT: CAR-T
February 12, 2018
Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond in Keystone, Colorado
Rapid production of T-cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes invivo memory (poster)
SUBJECT: CAR-T
December 09, 2017
59th American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta
SUBJECT: CAR-T
SUBJECT: CAR-T
Autologous T cells modified to co-express CD33-specific chimeric antigen receptor and a kill switch for treatment of CD33+ acute myeloid leukemia
SUBJECT: CAR-T
SUBJECT: CAR-T
September 1, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Clinical data from first generation CD19-specific CAR-T cells, manufactured using Sleeping Beauty gene transfer, administered to ALL and NHL patients undergoing HSCT. Read more
SUBJECT: CAR-T
December 07, 2015
American Society of Hematology Annual Meeting
Pre-emptive infusion with CD19-directed, CAR-modified T cells infused after autologous or allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies
SUBJECT: CAR-T
Back to TOP